Nivolumab/pembrolizumab: Various toxicities and lack of efficacy: 17 case reports.
In: Reactions Weekly, Jg. 1929 (2022-10-22), Heft 1, S. 506-506
serialPeriodical
Zugriff:
However, 6 patients out of the 17 patients showed progression of the malignant melanoma (indicating lack of efficacy) and 17 patients developed nephritis, arthritis, hypothyroidism, itch, mucositis, skin rash or thyroiditis secondary to pembrolizumab or nivolumab. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study conducted between January 2017 and September 2021 involving 39 patients treated for malignant melanoma, 17 patients (9 men and 8 women) aged 36-86 years were described; amongst the 17 patients 16 patients developed nephritis, arthritis, hypothyroidism, itch, mucositis, skin rash or thyroiditis during treatment with pembrolizumab or nivolumab for malignant melanoma. Between 25 May 2017 and 5 May 2021, the patients started receiving pembrolizumab or nivolumab (which included 2 patients who received both pembrolizumab and nivolumab. [Extracted from the article]
Titel: |
Nivolumab/pembrolizumab: Various toxicities and lack of efficacy: 17 case reports.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 1929 (2022-10-22), Heft 1, S. 506-506 |
Veröffentlichung: | 2022 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-022-26130-z |
Schlagwort: |
|
Sonstiges: |
|